BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target

BTIG analyst Thomas Shrader has reiterated a Buy rating on NRX Pharmaceuticals (NASDAQ: NRXP) and maintained a price target of $25 for the stock. This endorsement reflects confidence in the company's performance and potential for growth.